 Home > Active Ingredient News > Drugs Articles > European Medicines Agency: mRNA new crown vaccine is not associated with autoimmune hepatitis

European Medicines Agency: mRNA new crown vaccine is not associated with autoimmune hepatitis

 Last Update: 2022-05-31
 Source: Internet
 Author: User

Tags

gpa autoimmune disease

minimalist journal

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, a study on "New crown vaccine may cause a rare T cell-mediated autoimmune hepatitis" published in the Journal of Hepatology, a journal in the field of liver disease The paper, which was finalized on March 31, 2022, refers to a case report in Germany of a 52-year-old man who developed a bimodal flare of acute hepatitis after receiving 2 doses of the mRNA vaccine

In this regard, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) announced on April 8 that there is currently no evidence to support a causal relationship between the mRNA new crown vaccine and autoimmune hepatitis (AIH), and no update is currently required.

There is currently no evidence to support a causal relationship between the mRNA new crown vaccine and autoimmune hepatitis (AIH), and there is currently no need to update the product information for the vaccine

Autoimmune hepatitis (AIH) is a very rare chronic progressive liver inflammatory disease mediated by an autoimmune response, according to the PRAC meeting minutes

The European Medicines Agency (EMA) said it will continue to closely monitor any new situation reports and take appropriate measures if necessary

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Tirzepatide Lyophilized powder Vial 5mg 10mg 15mg 20mg 30mg customize 99% Purity with third side checking report

CAS No.: 2023788-19-2

Pharmacy Grade

$50-60/UNIT FOB

Wight loss Lyophilized Semaglutide Petide powder CAS 910463-68-2 with 99.9% purity

CAS No.: 910463-68-2

Pharmacy Grade

$140-175/G FOB

High Quality (E,E,E,E)-Squalene CAS NO 111-02-4 GMP ISO9001 EP Pharma grade Manufacture

CAS No.: 111-02-4

EP Pharma grade

$400-405/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.